Loading…
HALEOS LABS (HALEOSLABS)₹1,402+0.14%Pharmaceuticals
In the Jun 2026 quarter (consolidated), HALEOS LABS reported sales of ₹72.83 Cr, down 11.6% from Jun 2025, and net profit of ₹1.83 Cr, down 58.2% year on year. For the year to Mar 2026, sales were ₹333 Cr and net profit ₹17.96 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69.14 | 71.92 | 89.90 | 92.50 | 78.37 | 84.46 | 88.95 | 82.38 | 81.23 | 94.70 | 75.01 | 72.83 |
| Expenses | 61.55 | 62.95 | 78.91 | 76.51 | 70.14 | 72.09 | 81.92 | 71.04 | 68.00 | 81.03 | 71.16 | 64.08 |
| Operating Profit | 7.91 | 9.28 | 11.35 | 16.24 | 8.55 | 12.72 | 7.41 | 11.69 | 13.55 | 14.03 | 4.15 | 9.10 |
| OPM % | 11.5% | 13.0% | 12.7% | 17.6% | 11.0% | 15.1% | 8.4% | 14.2% | 16.8% | 14.9% | 5.6% | 12.5% |
| Other Income | 0.28 | 0.59 | 2.37 | 0.43 | 2.05 | 0.07 | 2.33 | 1.01 | 0.43 | 0.19 | 2.02 | 0.47 |
| Interest | 2.82 | 2.35 | 2.85 | 2.41 | 2.15 | 2.15 | 2.04 | 1.88 | 1.63 | 1.55 | 1.43 | 1.91 |
| Depreciation | 3.74 | 3.74 | 3.79 | 3.67 | 3.75 | 3.77 | 3.79 | 3.81 | 3.88 | 3.90 | 3.84 | 4.23 |
| Profit before tax | 1.67 | 3.82 | 7.12 | 10.69 | 4.73 | 6.94 | 3.95 | 7.05 | 8.52 | 8.82 | 0.91 | 3.45 |
| Tax % | 126.5% | −8.2% | 8.7% | 33.3% | 29.8% | 29.8% | 11.5% | 37.6% | 24.4% | 24.3% | 62.2% | 46.5% |
| Net Profit | −0.43 | 4.11 | 6.45 | 7.08 | 3.29 | 4.85 | 3.47 | 4.38 | 6.40 | 6.63 | 0.34 | 1.83 |
| EPS (Rs) | 2.26 | 14.27 | 19.60 | 23.22 | 15.51 | 18.17 | 9.86 | 13.81 | 20.24 | 21.98 | 1.47 | 8.80 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 261 | 266 | 349 | 316 | 306 | 344 | 333 | 324 |
| Expenses | 344 | 236 | 236 | 317 | 288 | 276 | 301 | 290 | 284 |
| Operating Profit | 34.95 | 24.97 | 29.94 | 34.92 | 28.95 | 30.96 | 44.93 | 44.90 | 40.83 |
| OPM % | 9.1% | 10.1% | 11.0% | 10.1% | 9.0% | 10.1% | 13.0% | 13.1% | 12.6% |
| Other Income | 2.01 | 2.01 | 2.01 | 13.99 | 5.01 | 4.01 | 4.99 | 2.01 | 3.11 |
| Interest | 6.02 | 5.02 | 5.02 | 6.02 | 7.03 | 10.04 | 9.04 | 6.02 | 6.52 |
| Depreciation | 5.99 | 8.01 | 7.99 | 10.01 | 11.01 | 15.01 | 14.99 | 14.99 | 15.85 |
| Profit before tax | 25.09 | 15.07 | 20.08 | 33.15 | 17.07 | 10.03 | 26.12 | 25.08 | 21.70 |
| Tax % | 30.0% | 31.0% | 31.0% | 23.0% | 31.0% | 36.0% | 28.0% | 29.0% | — |
| Exceptional items | −0.07 | 0.04 | 0.02 | 9.50 | 1.57 | 0.00 | 0.03 | 0.00 | — |
| Net Profit | 17.94 | 9.97 | 13.97 | 24.94 | 10.97 | 5.98 | 18.94 | 17.96 | 15.20 |
| EPS (Rs) | 59.28 | 33.82 | 45.05 | 84.06 | 38.03 | 30.20 | 66.82 | 57.48 | 52.49 |
| Dividend payout % | 3.0% | 0.0% | 3.0% | 2.0% | 4.0% | 5.0% | 2.0% | 3.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.01 | 2.99 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 211 |
| Borrowings | 46.99 | 64.99 | 64.99 | 79.93 | 99.95 | 101 | 85.96 | 111 |
| Other Liabilities | 116 | 71.94 | 108 | 125 | 126 | 114 | 107 | 130 |
| Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Fixed Assets | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 268 |
| CWIP | 2.99 | 15.97 | 37.93 | 50.90 | 0.99 | 5.99 | 0.00 | 9.98 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 176 |
| Inventories | 80.83 | 63.86 | 61.84 | 84.82 | 85.88 | 80.86 | 66.81 | 79.87 |
| Trade receivables | 40.98 | 21.99 | 34.02 | 34.01 | 45.98 | 51.02 | 69.02 | 61.05 |
| Cash & equivalents | 2.99 | 7.99 | 11.01 | 3.99 | 3.99 | 0.99 | 1.99 | 1.99 |
| Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 29.94 | 14.95 | 34.91 | −10.98 | 14.95 | 23.91 | 33.88 | 36.90 |
| Cash from investing activity | −44.13 | −27.10 | −26.08 | −7.03 | −31.11 | −18.08 | −15.05 | −58.25 |
| Cash from financing activity | 15.04 | 12.03 | −3.01 | 11.03 | 17.04 | −7.02 | −19.05 | 21.05 |
| Net cash flow | 1.01 | 0.00 | 6.01 | −8.01 | 0.00 | −1.01 | 0.00 | 1.01 |
| Capex | 23.94 | 22.96 | 35.89 | 50.88 | 48.89 | 20.96 | 14.96 | 57.85 |
| Free cash flow | 6.01 | −9.01 | 0.00 | −53.01 | −28.02 | 4.01 | 18.99 | −20.99 |
| CFO / OP % | 105.0% | 69.0% | 133.0% | −9.9% | 62.0% | 88.0% | 94.1% | 98.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 40 | 30 | 47 | 35 | 53 | 61 | 73 | 67 |
| Inventory days | 117 | 150 | 165 | 160 | 185 | 197 | 161 | 211 |
| Days payable | 141 | 102 | 164 | 147 | 128 | 144 | 127 | 163 |
| Cash conversion cycle | 16 | 78 | 48 | 48 | 110 | 115 | 106 | 116 |
| Working capital days | 13 | 17 | 1 | 16 | 23 | 10 | 6 | 4 |
| ROCE % | — | 12.0% | 12.9% | 11.9% | 8.0% | 7.0% | 11.9% | 10.0% |
For the Jun 2026 quarter, HALEOS LABS reported sales of ₹72.83 Cr, down 11.6% year on year and net profit of ₹1.83 Cr, down 58.2% year on year. The operating margin was 12.5%.
HALEOS LABS' sales for the year to Mar 2026 were ₹333 Cr; over the last twelve months they were ₹324 Cr.
Net profit for the year to Mar 2026 was ₹17.96 Cr, and ₹15.20 Cr over the last twelve months. Earnings per share over the same trailing period were ₹52.49.
HALEOS LABS reported borrowings of ₹111 Cr at Mar 2026, against cash and equivalents of ₹1.99 Cr.
Cash from operations was ₹36.90 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹20.99 Cr.